CARY, NC – May 1, 2025 – WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the successful completion of the sale of its electronic clinical outcomes assessment (eCOA*) business to Clario. The strategic divestiture allows WCG to concentrate on its core competencies as a trusted partner in connecting sponsors and CROs with sites to streamline study planning, optimize study reviews, accelerate start-up, and enable site operations. Leveraging its AI-enabled data, technology, and expertise, WCG reaffirms its commitment to accelerating clinical research and paving the way to bring life-saving therapies to patients.
This distinct approach allows WCG to:
- Architect the design and review of studies with speed and precision, grounded in more than 55 years of leadership in study review;
- Empower studies and sites to reach milestones faster through integrated technology, expertise, and streamlined processes; and
- Provide actionable insights using one of the industry’s most robust data sets to support critical decisions across the study lifecycle.
“This successful transition marks a pivotal moment for WCG. We appreciate the eCOA team’s work and expect their continued leadership in the future,” said Sam Srivastava, chief executive officer, WCG. “By now concentrating on our core strengths, we ensure that clinical research processes are optimized, timely, and impactful—ultimately accelerating the delivery of therapies that make a difference in patients’ lives.”
This divestiture symbolizes a promising horizon for WCG, strengthening its resolve to pioneer advancements in clinical research and ensuring the continued pursuit of excellence in healthcare innovation.
* WCG’s eCOA business is comprised of legacy companies – MedAvante-Prophase, VeraSci, and Analgesic Solutions.